Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
NCT ID: NCT05399992
Last Updated: 2026-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
847 participants
OBSERVATIONAL
2022-09-12
2026-10-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
NCT05362903
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
NCT05763875
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT03397121
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
NCT04659863
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies
NCT05682378
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inclisiran cohort
Participants prescribed inclisiran alone or with other LLTs as per approved label
Inclisiran
Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inclisiran
Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants with hypercholesterolemia having a diagnosis of ASCVD, ASCVD RE or HeFH
3. Participants who are not at LDL-C goal as per their CV risk according to respective clinical guidelines
4. Participants who per physician's criteria need to optimize their LLT
5. Participants who provide written informed consent to participate in the study
6. Participants who initiate inclisiran under conditions per local label and have LDL-C values available at baseline or within 3 months before treatment initiation.
Exclusion Criteria
2. Participants participating in a clinical trial with investigational product 3 Participants switching from previous PCSK9 mab treatment (within 90 days prior to Index date)
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Feldkirch, , Austria
Novartis Investigative Site
Graz, , Austria
Novartis Investigative Site
Linz, , Austria
Novartis Investigative Site
Sankt Veit im Pongau, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Shenzhen, Guangdong, China
Novartis Investigative Site
Holon, Gush Dan, Israel
Novartis Investigative Site
Petah Tikva, , Israel
Novartis Investigative Site
Tel Aviv, , Israel
Novartis Investigative Site
Kuala Lumpur, Kuala Lumpur, Malaysia
Novartis Investigative Site
Kuala Lumpur, , Malaysia
Novartis Investigative Site
Riyadh, Saudi, Saudi Arabia
Novartis Investigative Site
Jeddah, , Saudi Arabia
Novartis Investigative Site
Tabuk, , Saudi Arabia
Novartis Investigative Site
Fribourg, CH, Switzerland
Novartis Investigative Site
Basel, , Switzerland
Novartis Investigative Site
Geneva, , Switzerland
Novartis Investigative Site
Lausanne, , Switzerland
Novartis Investigative Site
Olten, , Switzerland
Novartis Investigative Site
Sankt Gallen, , Switzerland
Novartis Investigative Site
Zurich, , Switzerland
Novartis Investigative Site
Zurich, , Switzerland
Novartis Investigative Site
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Novartis Investigative Site
Dubai, United Arab Emirates, United Arab Emirates
Novartis Investigative Site
Abu Dhabi, , United Arab Emirates
Novartis Investigative Site
Al Ain City, , United Arab Emirates
Novartis Investigative Site
Dubai, , United Arab Emirates
Novartis Investigative Site
High Wycombe, Buckinghamshire, United Kingdom
Novartis Investigative Site
Louth, Lincolnshire, United Kingdom
Novartis Investigative Site
Sunderland, Tyne and Wear, United Kingdom
Novartis Investigative Site
Belfast, , United Kingdom
Novartis Investigative Site
Bromwich, , United Kingdom
Novartis Investigative Site
Burton-on-Trent, , United Kingdom
Novartis Investigative Site
Cardiff, , United Kingdom
Novartis Investigative Site
Hull, , United Kingdom
Novartis Investigative Site
Lancaster, , United Kingdom
Novartis Investigative Site
Liverpool, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
Middlesex, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CKJX839A12401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.